Overview

Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients

Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The Purpose of this study is to assess the Safety, Tolerability and Efficacy of Intravenous Cabaletta® in Oculopharyngeal Muscular Dystrophy (OPMD) Patients.
Phase:
Phase 2
Details
Lead Sponsor:
Bioblast Pharma Ltd.